Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study

被引:464
作者
Gallamini, A
Stelitano, C
Calvi, R
Bellei, M
Mattei, D
Vitolo, U
Morabito, F
Martelli, M
Brusamolino, E
Iannitto, E
Zaja, F
Cortelazzo, S
Rigacci, L
Devizzi, L
Todeschini, G
Santini, G
Brugiatelli, M
Federico, M
机构
[1] Az Osped S Croce & Carle, I-12100 Cuneo, Italy
[2] Azienda Osped Bianchi Melacrino Morelli, Div Ematol, Reggio Di Calabria, Italy
[3] Univ Modena, Cattedra Oncol Med, I-41100 Modena, Italy
[4] Azienda Ospedaliera S Giovanni Battista, Turin, Italy
[5] Azienda Osp Bianchi Melacrino Morelli, Ctr Trapianti Midollo Osseo, Reggio Di Calabria, Italy
[6] Policlin San Matteo, IRCCS, Div Ematol, I-27100 Pavia, Italy
[7] Univ Palermo, Dipartimento Oncol, Unita Ematol & TMO, Palermo, Italy
[8] Univ Roma La Sapienza, Dipartimento Biotecnol Cellulari & Ematol, Rome, Italy
[9] Policlin Univ, Clin Ematol, Dipartimento Ric Med & Morfol, Udine, Italy
[10] Azienda Osped Osped Riuniti Bergamo, Div Ematol, Bergamo, Italy
[11] Policlin Careggi, Cattedra Ematol, Florence, Italy
[12] Policlin Careggi, Div Ematol, Florence, Italy
[13] Ist Nazl Tumori, Div Oncol Med C, I-20133 Milan, Italy
[14] Univ Verona, Cattedra Ematol, I-37100 Verona, Italy
[15] Azienda Osped Osped S Martino, Div Ematol, Genoa, Italy
[16] Azienda Osped Papardo, Div Ematol, Messina, Italy
关键词
D O I
10.1182/blood-2003-09-3080
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To assess the prognosis of peripheral T-cell lymphoma unspecified, we retrospectively analyzed 385 cases fulfilling the criteria defined by the World Health Organization classification. Factors associated with a worse overall survival (OS) in a univariate analysis were age older than 60 years (P=.0002), equal to or more than 2 extranodal sites (P=.0002), lactic dehydrogenase (LDH) value at normal levels or above (P<.0001), performance status (PS) equal to or more than 2 (Pless than or equal to.0001), stage III or higher (P=.0001), and bone marrow involvement (P=.0001). Multivariate analysis showed that age (relative risk, 1.732; 95% CI, 1.300-2.309; P<.0001), PS (relative risk, 1.719; 95% CI, 1.269-2.327, P<.0001), LDH level (relative risk, 1.905; 95% CI, 1.415-2.564; P<.0001), and bone marrow involvement (relative risk, 1.454; 95% CI, 1.045-2.023; P=.026) were factors independently predictive for survival. Using these 4 variables we constructed a new prognostic model that singled out 4 groups at different risk: group 1, no adverse factors, with 5-year and 10-year OS of 62.3% and 54.9%, respectively; group 2, one factor, with a 5-year and 10-year OS of 52.9% and 38.8%, respectively; group 3, 2 factors, with 5-year and 10-year OS of 32.9% and 18.0%, respectively; group 4,3 or 4 factors, with a 5-year and 10-year OS of 18.3 and 12.6%, respectively (Pless than or equal to.0001; log-rank, 66.79). (C) 2004 by The American Society of Hematology.
引用
收藏
页码:2474 / 2479
页数:6
相关论文
共 28 条
  • [11] World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting - Airlie House, Virginia, November 1997
    Harris, NL
    Jaffe, ES
    Diebold, J
    Flandrin, G
    Muller-Hermelink, HK
    Vardiman, J
    Lister, TA
    Bloomfield, CD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (12) : 3835 - 3849
  • [12] HARRIS NL, 1994, BLOOD, V84, P1361
  • [13] NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS
    KAPLAN, EL
    MEIER, P
    [J]. JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) : 457 - 481
  • [14] SIMILAR OUTCOME OF TREATMENT OF B-CELL AND T-CELL DIFFUSE LARGE-CELL LYMPHOMAS - THE STANFORD EXPERIENCE
    KWAK, LW
    WILSON, M
    WEISS, LM
    DOGGETT, R
    DORFMAN, RF
    WARNKE, RA
    HORNING, SJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (08) : 1426 - 1431
  • [15] Peripheral T-cell lymphomas: Initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the REAL Classification
    Lopez-Guillermo, A
    Cid, J
    Salar, A
    Lopez, A
    Montalban, C
    Castrillo, JM
    Gonzalez, M
    Ribera, JM
    Brunet, S
    Garcia-Conde, J
    de Sevilla, AF
    Bosch, F
    Montserrat, E
    [J]. ANNALS OF ONCOLOGY, 1998, 9 (08) : 849 - 855
  • [16] MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163
  • [17] Evaluation of the revised European-American lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma
    Melnyk, A
    Rodriguez, A
    Pugh, WC
    Cabannillas, F
    [J]. BLOOD, 1997, 89 (12) : 4514 - 4520
  • [18] NIE HH, 1979, SPSS STAT PACK SOC S
  • [19] STAGE IS A BETTER PROGNOSTIC INDICATOR THAN MORPHOLOGIC SUBTYPE IN PRIMARY NONCUTANEOUS T-CELL LYMPHOMA
    NOORDUYN, LA
    VANDERVALK, P
    VANHEERDE, P
    VROOM, TM
    BLOK, P
    WILLEMZE, R
    MEIJER, CJLM
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1990, 93 (01) : 49 - 57
  • [20] PAN L, 1991, CLIN EXP IMMUNOL, V86, P240